James Andress, who headed Beecham's worldwide pharmaceutical business prior to the company's merger with SmithKline, named to the board of the privately held biotechnology company. Prior to joining Beecham, Andress served as president and chief operating officer at Sterling Drug. He currently is president and CEO of Information Resources, Inc.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.